TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06128551: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Sponsor: Revolution Medicines, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 534 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT06128551 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06128551 Rescue Dossier →